Nuclear medicine 2013: from status quo to status go
- PDF / 98,785 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 80 Downloads / 202 Views
EDITORIAL
Nuclear medicine 2013: from status quo to status go Thomas Beyer & Marcus Hacker & August Schubiger & Irene Virgolini & Hans-Jürgen Wester
Received: 29 August 2013 / Accepted: 30 August 2013 / Published online: 3 October 2013 # Springer-Verlag Berlin Heidelberg 2013
For decades nuclear medicine has been fostered as a selfsustaining medical monoculture. Since the 1950s, when focusing on the thyroid gland, nuclear medicine physicians were confident in embracing a holistic approach to the diagnosis and therapy of thyroid diseases. At the time, radionuclide therapy was introduced with the clinical adoption of 131I-iodide for the diagnosis and therapy of differentiated thyroid carcinoma. This early theranostic concept reflects a prime example of the inherent capabilities of nuclear medicine: to use the same biomolecule both for assessing the extent of a disease and for
This editorial represents the essence of the discussions during the 8th Tyrolean Nuclear Medicine Symposium on 28 June 2013 in Innsbruck, Austria, held in honour of the 80th birthday of Prof. Georg Riccabona. T. Beyer (*) Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University of Vienna, Waehringer Guertel 18-20/4L, A-1090 Vienna, Austria e-mail: [email protected] M. Hacker Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria T. Beyer : M. Hacker Research Cluster Imaging, Medical University of Vienna, Vienna, Austria A. Schubiger Collegium Helveticum, Transdisciplinary Laboratory, ETH and UZH Zurich, Zurich, Switzerland I. Virgolini Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria H.
Data Loading...
